ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders
Optimizing vaccine design for Alzheimer’s disease
TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming AD/PDTM International Conference, to be held in Barcelona Spain, March 15-20, 2022.
ProMIS Chief Development Officer, Dr. Johanne Kaplan, will deliver an on-site oral presentation “Optimizing vaccine design for Alzheimer’s disease: selective targeting of computationally-derived conformational B cell epitopes of soluble amyloid-beta toxic oligomers" as part of the AD/PDTM symposium entitled: “Abeta and other targeting therapies in AD”. The symposium is to be held on Sunday, March 20, 9:05-11:05 AM, local time, in room 113 at the International Barcelona Convention Center.
The presentation discusses the optimal design of an amyloid-beta (Abeta) vaccine to elicit antibodies that are selective for toxic Abeta oligomers (ABO) without inducing a potentially detrimental immune response to normal forms of Abeta.
Dr. Kaplan’s presentation will be available on the ProMIS website (www.promisneurosciences.com) at the conclusion of the AD/PDTM Conference on March 20th.
AD/PDTM is the groundbreaking series of Alzheimer’s and Parkinson’s Diseases Conferences attracting international medical and scientific professionals worldwide. The Conference is at the forefront of unraveling the mechanisms and improving the treatment of Alzheimer’s, Parkinson’s, and other related neurodegenerative diseases. AD/PD™ Conferences uniquely combine distinct neurodegenerative diseases in one setting and examine their similarities and differences; there is a strong focus on mechanisms of disease, prevention, and therapy.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing therapeutics selectively targeting toxic misfolded oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary computational modeling techniques. The Company applies its molecular dynamics, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Released March 10, 2022